Lookup NU author(s): Dr Miranda Patterson,
Dr Yvette Drew,
Professor Nicola Curtin
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© Springer Science+Business Media New York 2017. All rights reserved. PARP enzymes synthese poly(ADP-ribose) (PAR) using nicotinamide adenine dinucleotide (NAD+) as a substrate. PARP-1 is the most extensively studied of a family of PARP enzymes. It is a highly abundant nuclear protein that is activated by DNA breaks and facilitates their repair. PARP inhibitors (PARPis), originally designed to enhance the activity of DNA damaging chemo- and radiotherapy can exploit defects in homologous recombination DNA repair (HRR) by a process termed synthetic lethality. This potential for tumour-selective non-toxic therapy with PARPi has proved the impetus to progress the development of these compounds further.
Author(s): Patterson MJ, Drew Y, Curtin NJ
Publication type: Book Chapter
Publication status: Published
Book Title: Cancer Therapeutic Targets
Online publication date: 09/04/2017
Acceptance date: 02/04/2016
Place Published: New York
Library holdings: Search Newcastle University Library for this item